Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Darren R. Feldman, Yasser Ged, Chung Han Lee, Andrea Knezevic, Ana M. Molina, Ying Bei Chen, Joshua Chaim, Devyn T. Coskey, Samuel Murray, Satish K. Tickoo, Victor E. Reuter, Sujata Patil, Han Xiao, Jahan Aghalar, Arlyn J. Apollo, Maria I. Carlo, Robert J. Motzer, Martin H. Voss

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences